Mais D E, Kochel P J, Saussy D L, Halushka P V
Mol Pharmacol. 1985 Aug;28(2):163-9.
A binding site for the thromboxane A2/prostaglandin H2 (TXA2/PGH2) antagonist 125I-PTA-OH (9,11-dimethylmethano-11,12-methano-16-(4-methoxyphenyl)-13,14-dih ydro-13-aza-1 5 alpha beta-w-tetranor-TXA2) to washed canine platelets is described. 127I-PTA-OH competitively antagonized aggregation induced by the TXA2/PGH2 mimetic U46619. A Schild analysis of the pharmacologic study revealed pA2 of 7.97 and a slope of -0.95. The pA2 value yielded a Kd of 11 nM. Specific binding in Tris-NaCl buffer (pH 7.4) is not affected by extracellular Ca2+ or Mg2+ in concentrations up to 750 microM. The pH optimum for binding resides between 7.0 and 7.4. The association rate constant, k1, was 4.5 X 10(6) M-1 min-1, and the dissociation rate constant, k-1, was 1.45 X 10(-1) min-1, yielding a kinetically determined Kd (k-1/k1) of 32 nM. Scatchard analysis of I-PTA-OH binding to washed canine platelets revealed two classes of binding sites, a high affinity site (Kd = 24 nM, Bmax = 71 fmol/10(7) platelets) (4400 binding sites/platelet) and a low affinity site (Kd = 2.1 microM). Several TXA2/PGH2 receptor antagonists competed with specific 125I-PTA-OH binding, and the rank order of potency for displacing the ligand correlated (r = 0.97) with the rank order of potency for their ability to inhibit U46619-induced aggregation in canine platelet-rich plasma. Prostaglandins F2 alpha and E2 also displaced the ligand, but only at much higher concentrations. Binding of I-PTA-OH or the TXA2/PGH2 mimetic U46619 was unaffected by the aggregating agents epinephrine (10 microM) or ADP (5 microM). The similarity in the Kd values obtained kinetically, by equilibrium binding studies for the high affinity site and by Schild analysis, suggests that this high affinity site mediates TXA2/PGH2 induced platelet aggregation. In addition, the close correlation between the abilities of the antagonists to displace the ligand and to inhibit U46619-induced aggregation suggests that this site may represent a TXA2/PGH2 receptor.
本文描述了血栓素A2/前列腺素H2(TXA2/PGH2)拮抗剂125I-PTA-OH(9,11-二甲基甲撑-11,12-甲撑-16-(4-甲氧基苯基)-13,14-二氢-13-氮杂-15αβ-w-四降-TXA2)与洗涤后的犬血小板的结合位点。127I-PTA-OH竞争性拮抗TXA2/PGH2模拟物U46619诱导的聚集。药理学研究的Schild分析显示pA2为7.97,斜率为-0.95。pA2值得出Kd为11 nM。在Tris-NaCl缓冲液(pH 7.4)中,浓度高达750 microM的细胞外Ca2+或Mg2+不影响特异性结合。结合的最适pH在7.0至7.4之间。缔合速率常数k1为4.5×10(6) M-1 min-1,解离速率常数k-1为1.45×10(-1) min-1,动力学测定的Kd(k-1/k1)为32 nM。对I-PTA-OH与洗涤后的犬血小板结合的Scatchard分析显示有两类结合位点,一个高亲和力位点(Kd = 24 nM,Bmax = 71 fmol/10(7)血小板)(4400个结合位点/血小板)和一个低亲和力位点(Kd = 2.1 microM)。几种TXA2/PGH2受体拮抗剂与特异性125I-PTA-OH结合竞争,取代配体的效价顺序与它们在富含犬血小板血浆中抑制U46619诱导聚集的能力的效价顺序相关(r = 0.97)。前列腺素F2α和E2也能取代配体,但仅在高得多的浓度下。I-PTA-OH或TXA2/PGH2模拟物U46619的结合不受聚集剂肾上腺素(10 microM)或ADP(5 microM)的影响。通过动力学获得的Kd值、高亲和力位点的平衡结合研究以及Schild分析之间的相似性表明,这个高亲和力位点介导TXA2/PGH2诱导的血小板聚集。此外,拮抗剂取代配体的能力与抑制U46619诱导聚集的能力之间的密切相关性表明,这个位点可能代表一个TXA2/PGH2受体。